In accordance with the aforementioned data, agrin-MuSK signaling axis has been proposed as a therapeutic target for myasthenia gravis and other neuromuscular disorders [178], thus reinforcing the importance of unveiling the role of agrin-MuSK pathway in tSCs during aging. The gene discussed is AGRN; the disease is myasthenia gravis.